EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.
Also called NCT06249945
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Registry
-
NCT06249945
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Taiwan
- Registry status
- Recruiting
Technical summary
Registry record NCT06249945. Randomized; single masking; primary purpose treatment. Start 2024-03-05 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
- Acronym
- EMPA-PRED
- Condition
- End Stage Renal Disease on Dialysis
- Intervention (Drug)
- Empagliflozin 25 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- National Taiwan University Hospital
- Collaborator
- Shin Kong Wu Ho-Su Memorial Hospital
Record details
- Record id
cardio:ct-nct06249945- Content hash
43251a6a06a54e99e336fc528fe6fea7be0087ee2210df468c654b53e83d551f